Kiora Pharmaceuticals (NASDAQ:KPRX) Announces Earnings Results

Kiora Pharmaceuticals (NASDAQ:KPRX) announced its quarterly earnings data on Friday. The company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.13, FiscalAI reports.

Kiora Pharmaceuticals Stock Performance

Shares of KPRX remained flat at $2.45 during midday trading on Friday. The stock had a trading volume of 40,835 shares, compared to its average volume of 64,626. The stock’s 50 day moving average is $2.21 and its 200-day moving average is $2.17. Kiora Pharmaceuticals has a 12-month low of $1.76 and a 12-month high of $4.18. The firm has a market cap of $10.85 million, a price-to-earnings ratio of -0.92 and a beta of -0.48.

Hedge Funds Weigh In On Kiora Pharmaceuticals

Several hedge funds have recently bought and sold shares of the company. Two Sigma Investments LP purchased a new position in Kiora Pharmaceuticals during the third quarter valued at approximately $33,000. Citadel Advisors LLC purchased a new position in shares of Kiora Pharmaceuticals during the 3rd quarter valued at $125,000. Renaissance Technologies LLC grew its position in shares of Kiora Pharmaceuticals by 71.0% during the 4th quarter. Renaissance Technologies LLC now owns 21,200 shares of the company’s stock valued at $42,000 after purchasing an additional 8,800 shares in the last quarter. DRW Securities LLC grew its position in shares of Kiora Pharmaceuticals by 199.2% during the 4th quarter. DRW Securities LLC now owns 110,282 shares of the company’s stock valued at $217,000 after purchasing an additional 73,417 shares in the last quarter. Finally, Alyeska Investment Group L.P. bought a new position in shares of Kiora Pharmaceuticals in the fourth quarter worth $152,000. Hedge funds and other institutional investors own 76.97% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Kiora Pharmaceuticals in a research note on Monday, April 27th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $10.00.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc (NASDAQ: KPRX) is a clinical-stage biotechnology company dedicated to developing innovative therapies for serious eye diseases. The company’s research efforts focus on modulating immune and neurological pathways in the eye to address conditions that currently have limited treatment options. Kiora’s approach combines small-molecule immunomodulators with advanced gene-based and optogenetic technologies to preserve and restore vision.

The company’s lead product candidate, KIO-100 (PP-001), is an intravitreal formulation designed to inhibit key inflammatory pathways implicated in non-infectious uveitis and other autoimmune ocular disorders.